Though serum levels of FGF19 presented no relationship with any of the liver enzymes or the liver inflammation grade in PBC-AIH OS patients, the BA synthesis suppression and potential immune disease-modifying activity characteristic of NGM282 may present an effective approach to treatment of PBC-AIH OS. The gene discussed is FGF19; the disease is immune system disorder.